Cizzle Biotechnology Converts £400,000 of Loan Notes Into New Equity

An update from Cizzle Biotechnology Holdings PLC ( (GB:CIZ) ) is now available.

Cizzle Biotechnology has received a notice from investor Frazer Lang to convert £400,000 of existing convertible loan notes into 28,571,429 new ordinary shares at 1.4 pence per share, strengthening its equity base and reducing outstanding debt. Following this conversion and a recent £100,000 drawdown from a new £250,000 convertible facility with the same investor, the note holder will retain £100,000 of loan notes and Cizzle will have 424,963,202 ordinary shares in issue, with the new shares expected to begin trading on or around 11 May 2026, affecting ownership percentages and voting rights for shareholders under FCA transparency rules.

Spark’s Take on CIZ Stock

According to Spark, TipRanks’ AI Analyst, CIZ is a Neutral.

The score is held down primarily by weak financial performance (pre-revenue, ongoing losses, cash burn, and a sharply reduced equity cushion), with technical indicators also pointing to subdued momentum. Valuation metrics provide limited support due to negative earnings and no dividend.

To see Spark’s full report on CIZ stock, click here.

More about Cizzle Biotechnology Holdings PLC

Cizzle Biotechnology Holdings is a UK-based diagnostics company focused on developing non-invasive, cost-effective blood tests for the early detection of lung cancer. Its lead technology is based on the CIZ1B biomarker, which is closely associated with early-stage lung cancer, and the company pursues commercial royalty-bearing licensing deals and collaborations with cancer care centres. Cizzle has been listed on the Standard segment of the London Stock Exchange’s main market since May 2021.

Average Trading Volume: 1,339,711

Technical Sentiment Signal: Buy

Current Market Cap: £10.5M

For an in-depth examination of CIZ stock, go to TipRanks’ Overview page.